This Article Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mehta, C. Articles by Ware, J. H. Search for Related Content PubMed PubMed Citation Articles by Mehta, C. Articles by Ware, J. H. Related Collections Cardiovascular Pharmacology Platelet function inhibitors Clinical Studies

(Circulation. 2009;119:597-605.)
© 2009 American Heart Association, Inc.

Statistical Primer for Cardiovascular Research

Optimizing Trial Design

Sequential, Adaptive, and Enrichment Strategies

Cyrus Mehta, PhD; Ping Gao, PhD; Deepak L. Bhatt, MD, MPH; Robert A. Harrington, MD; Simona Skerjanec, PharmD; James H. Ware, PhD

From the Harvard School of Public Health, Boston, Mass (C.M., J.H.W.); Cytel Statistical Software and Services, Cambridge, Mass (C.M.); The Medicines Company, Parsippany, NJ (P.G., S.S.); Veterans Affairs Boston Healthcare System and Brigham and Women’s Hospital, Boston, Mass (D.L.B.); and Duke Clinical Research Institute, Durham, NC (R.A.H.).

Correspondence to Cyrus Mehta, PhD, Cytel Statistical Software and Services, 675 Massachusetts Ave, Cambridge, MA 02139. E-mail mehta@cytel.com

Key Words: statistics • clinical trials • methods • design • angioplasty

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Despite substantial progress in the prevention of cardiovascular disease and its ischemic complications, it remains the single largest killer in the United States. New treatment options are needed, particularly to respond to the challenges of an aging population and rising rates of obesity and diabetes. Development of novel therapeutic strategies for the management of acute cardiovascular disease is especially challenging. Specific problems include relatively low event rates, diverse patient populations, lack of reliable surrogate end points, and small treatment effects subject to substantial uncertainty. Because the clinical development process is enormously expensive and time consuming, there is considerable interest in statistical methods that use accumulating data from a clinical trial to inform and modify its design. Such redesign might include changes in target sample size and even changes in the target population. This article discusses developments in adaptive design of interest to cardiovascular research.

To illustrate the methods we discuss, we focus on the development of novel therapies for the management of acute coronary syndromes. However, the ideas we discuss have much wider application. We begin by discussing the traditional approach to determination of a fixed sample size for a clinical trial. We then describe group sequential designs and the benefit they provide in the conduct of trials. In the section on Adaptive Sample Size Reestimation, we discuss designs that are adaptive in the sense that they allow an adjustment of the target sample size based on the accumulating data from the trial. In the section on Adaptive Sample Size . . . [Full Text of this Article]

This article has been cited by other articles:

				J. Loscalzo Pilot Trials in Clinical Research: Of What Value Are They? Circulation, April 7, 2009; 119(13): 1694 - 1696. [Full Text] [PDF]